About Cyclerion Therapeutics, Inc. (CYCN)
Cyclerion Therapeutics, Inc., a biopharmaceutical company, develops treatments for serious diseases serious diseases with novel sGC stimulators in both the central nervous system (CNS) and the periphery. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to treat cardiovascular diseases; and Praliciguat, a systemic sGC stimulator for the treatment of rare kidney disease. It has a license agreement with Akebia to develop, manufacture, medical affair, and commercializes Praliciguat and other related products. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
CYCN Key Statistics
| Current Price | $1.39 | Market Cap | $5 million |
|---|---|---|---|
| Daily Change | +0.00% | Volume | 65K |
| 52-Week High | $3.79 | 52-Week Low | $1.03 |
| Sector | Healthcare | Industry | Biotechnology |
CYCN Price Performance
Cyclerion Therapeutics, Inc. stock has returned +0.00% over the past day, +6.11% over the past week, +14.88% over the past month, and -9.15% over the past three months. The stock trades between a 52-week low of $1.03 and a high of $3.79.